Search

Your search keyword '"Queizán JA"' showing total 2 results
Start Over Author "Queizán JA" Topic antineoplastic combined chemotherapy protocols
2 results on '"Queizán JA"'

1. Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).

Author

Tomás JF, Montalbán C, De Sevilla AF, Martínez-López J, Díaz N, Canales M, Martínez R, Sánchez-Godoy P, Caballero MD, Peñalver J, Prieto E, Salar A, Burgaleta C, Queizán JA, Bajo R, De Oña R, and De La Serna J

Subjects
Adult, Aged, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Murine-Derived adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Chemotherapy, Adjuvant, Clinical Trials as Topic, Cooperative Behavior, Cyclophosphamide adverse effects, Drug Administration Schedule, Drug-Related Side Effects and Adverse Reactions epidemiology, Female, Humans, Male, Middle Aged, Neoadjuvant Therapy, Rituximab, Spain, Treatment Outcome, Vidarabine administration & dosage, Vidarabine adverse effects, Young Adult, Antibodies, Monoclonal, Murine-Derived administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cyclophosphamide administration & dosage, Lymphoma, Follicular drug therapy, Vidarabine analogs & derivatives
Abstract

We assessed the efficacy of fludarabine, cyclophosphamide, and rituximab in combination (FCR) as frontline treatment in patients with follicular lymphoma (FL) followed by rituximab maintenance. Seventy-five untreated patients with FL received FCR followed by maintenance with rituximab 375 mg/m(2) weekly during 4 weeks and every 6 months for 2 years. The overall response rate was 100%, with 89% complete remission (CR) and 11% partial remission (PR). Molecular remission was observed in all but one patient. Only eight patients completed all therapy planned. With a median follow-up of 47 months, the 5-year overall survival (OS), progression-free survival (PFS), and event-free survival (EFS) were 77%, 93%, and 72%, respectively. Age below 60 and low Follicular Lymphoma International Prognostic Index (FLIPI) correlated with a better EFS. Ten patients died due to toxic complications. The FCR regimen is highly effective in untreated patients with FL, with 89% CR, including molecular responses, and a low progression rate. However, the high incidence of treatment-related mortality makes this regimen unsafe and it cannot be recommended as an upfront therapy in FL.

Published
2011
Full Text
View/download PDF

2. Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.

Author

Martínez-López J, Rivero A, Rapado I, Montalbán C, Paz-Carreira J, Canales M, Martínez R, Sánchez-Godoy P, Fernández de Sevilla A, Peñalver FJ, Gonzalez M, Prieto E, Salar A, Burgaleta C, Queizán JA, Peñarrubia MJ, Monteagudo MD, Cabrera C, De la Serna J, and Tomás JF

Subjects
Adult, Aged, Alleles, Anti-Infective Agents therapeutic use, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal, Murine-Derived, Antineoplastic Combined Chemotherapy Protocols adverse effects, Clinical Trials, Phase II as Topic statistics & numerical data, Cyclophosphamide administration & dosage, Cyclophosphamide adverse effects, Early Termination of Clinical Trials, Female, Gene Frequency, Genetic Predisposition to Disease, Genetic Variation, Haplotypes genetics, Humans, Infections etiology, Infections genetics, Lymphoma, Follicular drug therapy, Lymphoma, Follicular epidemiology, Lymphopenia chemically induced, Lymphopenia complications, Male, Middle Aged, Multicenter Studies as Topic, Neutropenia chemically induced, Neutropenia complications, Prospective Studies, Risk, Rituximab, Spain epidemiology, Vidarabine administration & dosage, Vidarabine adverse effects, Vidarabine analogs & derivatives, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Infections epidemiology, Lymphoma, Follicular genetics, Mannose-Binding Lectin genetics
Abstract

The employment of current treatments based on chemotherapy and immunotherapy leads to inmunosuppression. The presence of mutations or polymorphisms in genes related to immune system might involve an additional disadvantage. The aim of the present study was to analyze mannose-binding lectin (MBL-2 gene) mutations and their association with severe infections and event-free survival in patients diagnosed with follicular lymphoma, treated uniformly, in the clinical trial LNHF-03. The results of this trial showed impressive clinical efficacy but was complicated with 80 documented infectious episodes. Patients were classified into two genotypic groups, AA and AO/OO, based on their haplotypic inheritance. Neither the number of infectious episodes nor differences in event-free survival was found as a function of MBL-2 groups. Other factors, including the lymphoma malignancy and the immune alterations associated with the disease, should be considered responsible for this observation.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results